Meeting of the National Vaccine Advisory Committee, 4192-4193 [2023-01218]

Download as PDF 4192 Federal Register / Vol. 88, No. 15 / Tuesday, January 24, 2023 / Notices REVISED RWHAP PART A TABLE UOB of federal funds by subprogram Category Federal funds authorized Prior year (FY 20XX) Unexpended carryover Current year (FY 20XX) Part A Formula. Part A Supplemental. Part A MAI. 2019 APPROVED ICR TABLE FOR RWHAP PART B UOB of federal funds by subprogram Category Part Part Part Part Part Part B B B B B A Federal funds authorized Unexpended carryover Current year (FY 20XX) Base. ADAP. Emerging Communities. MAI. ADAP Supplemental. Transfer. REVISED RWHAP PART B TABLE UOB of federal funds by subprogram Category Part Part Part Part Part Part B B B B B A Federal funds authorized Prior year (FY 20XX) Unexpended carryover Current year (FY 20XX) Base. ADAP. Emerging Communities. MAI. ADAP Supplemental. Transfer. RWHAP PART B REBATE TABLE Ryan White Rebate Funding Total Rebates Available. Expended Rebate Amount. Unexpended Rebate. Expended Rebate Amount to be Used to Reduce UOB. tkelley on DSK125TN23PROD with NOTICES HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. [FR Doc. 2023–01288 Filed 1–23–23; 8:45 am] BILLING CODE 4165–15–P 19:17 Jan 23, 2023 Meeting of the National Vaccine Advisory Committee Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the National Vaccine Advisory Committee (NVAC) will hold a virtual meeting. The meeting will be open to the public and public comment will be heard during the meeting. SUMMARY: Maria G. Button, Director, Executive Secretariat. VerDate Sep<11>2014 DEPARTMENT OF HEALTH AND HUMAN SERVICES Jkt 259001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 The meeting will be held February 2–3, 2023. The confirmed meeting times and agenda will be posted on the NVAC website at https:// www.hhs.gov/nvpo/nvac/meetings/ index.html as soon as they become available. DATES: Instructions regarding attending this meeting will be posted online at: https://www.hhs.gov/nvpo/ nvac/meetings/ at least one week prior to the meeting. Preregistration is required for those who wish to attend the meeting virtually or participate in public comment. Please register at https://www.hhs.gov/nvpo/ nvac/meetings/. FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal Officer, Office of Infectious Disease and HIV/AIDS Policy, U.S. Department of ADDRESSES: E:\FR\FM\24JAN1.SGM 24JAN1 Federal Register / Vol. 88, No. 15 / Tuesday, January 24, 2023 / Notices Health and Human Services, Tower Building, Room, 1101 Wootton Parkway, Rockville, MD 20852. Email: nvac@hhs.gov. Phone: 202–795–7697. DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of HHS was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. During this meeting, NVAC will hear presentations to support the recent charges on innovation and safety from Admiral Rachel L. Levine, MD, the Assistant Secretary for Health and Director of the National Vaccine Program. NVAC will also hear presentations on COVID–19, RSV, meningitis, and measles. Please note that agenda items are subject to change, as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: https://www.hhs.gov/nvpo/ nvac/. Members of the public will have the opportunity to provide comment at the NVAC meeting during the public comment period designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Individuals are welcome to submit written comments in advance. Written comments should not exceed three pages in length. Individuals submitting comments should email their written comments or their request to provide a comment during the meeting to nvac@ hhs.gov at least five business days prior to the meeting. National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting SUPPLEMENTARY INFORMATION: tkelley on DSK125TN23PROD with NOTICES Dated: January 5, 2023. Ann Aikin, Acting Designated Federal Official, Office of the Assistant Secretary for Health. [FR Doc. 2023–01218 Filed 1–23–23; 8:45 am] BILLING CODE 4150–44–P VerDate Sep<11>2014 19:17 Jan 23, 2023 National Institutes of Health Notice is hereby given of a change in the meeting of the Biomedical Research Study Section, March 7, 2023, 8:30 a.m. to March 7, 2023, 5:00 p.m., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on December 19, 2022, FR Doc 2022–27418, 87 FR 77623. This notice is being amended to change the Contact Person to Anna Ghambaryan, M.D., Ph.D., Scientific Review Officer, Extramural Project Review Branch, Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 2120, MSC 6902, Bethesda, MD 20892, (301) 443– 4032, anna.ghambaryan@nih.gov. The meeting is closed to the public. Dated: January 19, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–01305 Filed 1–23–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Chronic Dysfunction and Integrative Neurodegeneration Study Section. Date: February 15–16, 2023. Time: 8:00 a.m. to 7:00 p.m. Jkt 259001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 4193 Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015. Contact Person: Bernard Rajeev Srambical Wilfred, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435–1042, bernard.srambicalwilfred@nih.gov. Name of Committee: Oncology 1—Basic Translational Integrated Review Group; Basic Mechanisms of Cancer Health Disparities Study Section. Date: February 15–16, 2023. Time: 8:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Sulagna Banerjee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (612) 309–2479, sulagna.banerjee@ nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group Reproductive, Perinatal and Pediatric Health Study Section. Date: February 16–17, 2023. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Cynthia Chioma McOliver, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1007G, Bethesda, MD 20892, (301) 594–2081, mcolivercc@csr.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Brain Injury and Neurovascular Pathologies Study Section. Date: February 16–17, 2023. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Alexander Yakovlev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5206, MSC 7846, Bethesda, MD 20892, 301–435– 1254, yakovleva@csr.nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Social Sciences and Population Studies B Study Section. Date: February 16–17, 2023. Time: 10:30 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Kate Fothergill, Ph.D., Scientific Review Officer, Center for E:\FR\FM\24JAN1.SGM 24JAN1

Agencies

[Federal Register Volume 88, Number 15 (Tuesday, January 24, 2023)]
[Notices]
[Pages 4192-4193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01218]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: Office of Infectious Disease and HIV/AIDS Policy, Office of the 
Assistant Secretary for Health, Office of the Secretary, Department of 
Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services (HHS) is hereby giving notice 
that the National Vaccine Advisory Committee (NVAC) will hold a virtual 
meeting. The meeting will be open to the public and public comment will 
be heard during the meeting.

DATES: The meeting will be held February 2-3, 2023. The confirmed 
meeting times and agenda will be posted on the NVAC website at https://www.hhs.gov/nvpo/nvac/meetings/ as soon as they become 
available.

ADDRESSES: Instructions regarding attending this meeting will be posted 
online at: https://www.hhs.gov/nvpo/nvac/meetings/ at least 
one week prior to the meeting. Pre-registration is required for those 
who wish to attend the meeting virtually or participate in public 
comment. Please register at https://www.hhs.gov/nvpo/nvac/meetings/.

FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal 
Officer, Office of Infectious Disease and HIV/AIDS Policy, U.S. 
Department of

[[Page 4193]]

Health and Human Services, Tower Building, Room, 1101 Wootton Parkway, 
Rockville, MD 20852. Email: [email protected]. Phone: 202-795-7697.

SUPPLEMENTARY INFORMATION: Pursuant to section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of HHS was 
mandated to establish the National Vaccine Program to achieve optimal 
prevention of human infectious diseases through immunization and to 
achieve optimal prevention against adverse reactions to vaccines. The 
NVAC was established to provide advice and make recommendations to the 
Director of the National Vaccine Program on matters related to the 
Program's responsibilities. The Assistant Secretary for Health serves 
as Director of the National Vaccine Program.
    During this meeting, NVAC will hear presentations to support the 
recent charges on innovation and safety from Admiral Rachel L. Levine, 
MD, the Assistant Secretary for Health and Director of the National 
Vaccine Program. NVAC will also hear presentations on COVID-19, RSV, 
meningitis, and measles. Please note that agenda items are subject to 
change, as priorities dictate. Information on the final meeting agenda 
will be posted prior to the meeting on the NVAC website: https://www.hhs.gov/nvpo/nvac/.
    Members of the public will have the opportunity to provide comment 
at the NVAC meeting during the public comment period designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are welcome to submit written comments in 
advance. Written comments should not exceed three pages in length. 
Individuals submitting comments should email their written comments or 
their request to provide a comment during the meeting to [email protected] 
at least five business days prior to the meeting.

    Dated: January 5, 2023.
Ann Aikin,
Acting Designated Federal Official, Office of the Assistant Secretary 
for Health.
[FR Doc. 2023-01218 Filed 1-23-23; 8:45 am]
BILLING CODE 4150-44-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.